Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

antiviral research

- PMLiVE

EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19

FDA approval has already been granted following positive phase 3 trials

- PMLiVE

Price hike for Pfizer/BioNTech COVID-19 vaccine as UK orders boosters for 2022

The UK will pay £22 a shot, up from £18 previously, as confirmation of the UK's COVID-19 booster campaign for this winter is awaited, while the EU and the US...

- PMLiVE

Valneva’s COVID-19 vaccine to be tested in older people

The trial for VLA2001 will involve people over the age of 56 in New Zealand and aims to generate additional safety and immunogenicity data in older people

- PMLiVE

South Korean company SK bioscience moves into phase 3 trials for its COVID-19 vaccine

Part of the Wave 2 vaccine programme, GBP510 will bolster South Korea’s domestic supply if successful

- PMLiVE

BioNTech to use COVID vaccine profits to “expand and accelerate” pipeline

Vaccine maker posts first-half profits of €3.9bn compared to a loss of €142m a year earlier as demand for the innovative mRNA jab remains strong

- PMLiVE

Moderna deal to build state-of-the-art manufacturing plant bolsters Canada’s vaccine production

The new manufacturing facility will enhance the country’s “rapid pandemic response capabilities”

- PMLiVE

AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria

Real-world data shows similar safety profile for Vaxzevria and mRNA-based jabs

- PMLiVE

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

COVID-19 vaccine generated $7.8bn in the second quarter of 2021 alone

- PMLiVE

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a bid to protect Remicade

- PMLiVE

Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels

South Korea-based study found AZ followed by Pfizer boosted antibody levels six-fold compared to two AZ doses

- PMLiVE

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

ARV-471 is currently in a phase 2 trial for the treatment of patients ER-positive, HER2-negative locally advanced or metastatic breast cancer

- PMLiVE

One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants

New real-world data from Canada shows vaccine efficacy was lower against milder symptomatic disease with one dose

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links